Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Sep 27, 2010

OpGen Closes $17M to Market Microbial Whole-Genome Analysis Platform

OpGen Closes $17M to Market Microbial Whole-Genome Analysis Platform

The Argus Optical Mapping System generates high-resolution genetic maps from single DNA molecules. [© Orlando Florin Rosu - Fotolia.com]

  • OpGen completed a $17 million Series B equity financing. The company will use the money to pad commercial initiatives for the recently launched platform for microbial whole-genome analysis, the Argus Optical Mapping System.

    The system utilizes optical-mapping technology to generate ordered, whole-genome genetic maps from single DNA molecules. It is not a gel, PCR, or sequencing-based approach, but rather a method for generating high-resolution genetic maps that can be used in strain typing, comparative genomics, and whole-genome sequence assembly.

    Scientists can use Argus Optical Maps to view and compare bacterial genomes to each other as well as to in silico sequences. They can reportedly elucidate genotype to phenotype relationships that would not be detected by other technologies.

    “This financing will support the marketing efforts for our Argus Optical Mapping System as we continue to drive market awareness and grow revenues,” says Douglas White, CEO of OpGen. “In addition, the new growth capital will fuel our efforts to expand into new markets including developing new applications that will complement sequencing technologies and help facilitate rapid completion of large genome mapping and finishing technologies currently under development at the company.”



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »